Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina’s announced partnerships with IBM’s Watson and Philips help shore up the firm's data-analysis capabilities and clinical diagnostic marketing efforts, respectively, but the announcement of a ...

Illumina remains by far the leader in the NGS sequencing market. After the divestment of Grail, Illumina's core business could become highly cash-generative again with close to 30% FCF margin to ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech company at ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina, the market leader in DNA sequencing equipment, said Monday that it has begun layoffs and will reduce its San Diego real estate footprint as part of an effort to slash annual expenses by $100 ...

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting ...

Recent advancements in next-generation sequencing have led to substantial increases in throughput, coupled with reduced expenses. Due to these improvements, the process of library preparation has ...

Aug 13 (Reuters) - Illumina (ILMN.O), opens new tab said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene ...